Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

US-based diagnostic software company Arkstone Medical Solutions has partnered with Peruvian medical technology company Neslab ...

A groundbreaking cannabinoid-based antimicrobial, Silvanex, fights drug-resistant infections with a synergy of silver, CBC ...

Antimicrobial resistance (AMR) presents a significant challenge to global health, necessitating innovative therapeutic ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

Antibiotics are often thought of as an easy cure to bacterial infections, but they could be fueling an urgent public health ...

Researchers have used artificial intelligence to identify 25 new protein compounds that can kill bacteria and fungi, ...

Antimicrobial resistance (AMR) happens when germs, like fungi and bacteria, develop the ability to defeat the drugs that are ...

A new ally is emerging in the increasingly urgent battle against superbugs – and you might have encountered it before at the ...

Disperazol Pharma, a leading biotechnology firm that develops compounds that dismantle biofilms of critical Gram—negative pathogens, today announced that it has joined the AMR Industry Alliance. AMR ...